TRENDS IN MORTALITY OF POTENTIAL PNEUMOCOCCAL PNEUMONIA IN COLOMBIA, 2006-2019

Intro: In 2010, PCV10 was introduced in the Colombian National Immunization Program (NIP) for children, with good vaccination coverage >82% since 2012. However, the NIP does not include routine pneumococcal vaccination for older adults. We assessed trends in mortality rate (MR) due to potential p...

Full description

Bibliographic Details
Main Authors: C. Parellada, L.F. Reyes, C. Beltran, M. Rojas, C. Zampirolli, A. Abreu, P. Pungartnik, J.C. Orengo, F. De La Hoz
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223005957
Description
Summary:Intro: In 2010, PCV10 was introduced in the Colombian National Immunization Program (NIP) for children, with good vaccination coverage >82% since 2012. However, the NIP does not include routine pneumococcal vaccination for older adults. We assessed trends in mortality rate (MR) due to potential pneumococcal pneumonia (PPP) from 2006-2019. Methods: This ecological time-series study used Colombian nationwide administrative databases. We analyzed the pre-PCV10 (2006-2009) and post-PCV10 (2012-2019) periods, excluding the years 2010 and 2011 (transition period). ICD-10 codes included J13-J18. MRs were calculated per 100,000 people and stratified by age groups (<1, 1-4, 5-17, 18-49, 50-59, 60-64 and ≥65 years). The percent of change was calculated by the difference between the average rate in the pre-PCV and post-PCV periods for each age group. Joinpoint regression analysis was performed to assess changes in MRs. Annual percent changes (APCs) for each line segment and average APC (AAPC) over 2006-2019 were estimated. Findings: During 2006-2019, there were 102,082 deaths due to PPP. The highest MRs were seen for the age groups <1 and ≥65 years. Mean MRs decreased in age groups <18 years in the post-PCV10 period. A decreasing trend was seen primarily in those <1 year (AAPC -6.8; 95%CI: -8.6;-5.1) and 1-4 years (AAPC -5.0; 95%CI: -7.2;-2.8%) from 2006-2019. In contrast, for the age groups 50-59 years and 60-64 years, there was a significant increasing trend (AAPC 1.6%;95%CI 1.7%-5.1% and AAPC 3.4; 95%CI: 1.7;5.1, respectively) from 2006-2019. In ≥65 years, there was a significant increasing trend from 2011-2016 (APC 6.6; 95% CI: 0.5;13.1), followed by a non-significative decrease trend from 2016-2019 (APC -2.8; 95%CI-10.4;5.5). Conclusion: This study provided additional evidence for the benefits of childhood PCV programs. For older adults, MR has been consistently higher in post-vaccination period compared to pre-vaccination. These findings can inform decision-makers about the needs for pneumococcal vaccination among older adults in Colombia.
ISSN:1201-9712